ECG-I Targeted Ablation for Persistent AF Not Responding to Pulmonary Vein Isolation Results of a Two Staged Strategy.
Launched by BARTS & THE LONDON NHS TRUST · Nov 11, 2020
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Atrial Fibrillation (AF) is the commonest heart rhythm disturbance and is associated with significant morbidity and mortality. Catheter ablation (CA) is a procedure where catheters (leads) are passed into the heart and energy is used to disrupt and isolate (by freezing or cauterising) heart tissue causing AF. CA is an established therapy for AF. Success rates for CA for paroxysmal AF lies in the region of 70% or better. However, success rates for persistent AF is much lower and estimates lie in the region of 30-60%.
Current CA protocols for AF centre on isolating the pulmonary veins (the p...
Gender
ALL
Eligibility criteria
- Patients with recurrent AF or atrial tachycardia within 1 year of ablation for persistent AF in the PHENOTYPE AF trial (NCT03394404). Original inclusion criteria for PHENOTYPE AF trial:
- • Persistent AF (i.e. episodes of AF that are continuous for \> 1 week)
- • Willing for ablation.
- • Age between 18 to 80.
- Exclusion Criteria:
- * Exclusions:
- • Continuous persistent AF \> 2 years duration
- • Left atrial diameter \> 5 cm
- • Severe left ventricular impairment (EF \< 40%)
- • New York Heart Association class 3 or 4 heart failure
- • Known hypertrophic cardiomyopathy, cardiac sarcoid or Arrhythmogenic Cardiomyopathy.
- • Known inherited arrhythmia such as Brugada or long QT syndromes
- • Valvular disease that is more than moderate
- • History of valve replacement (metallic or tissue)
- • History of congenital heart disease (other than patent foramen ovale)
- • Previous left atrial ablation (percutaneous or surgical)
- • Cardiac surgery or percutaneous coronary intervention within the last 3 months.
- • Myocardial infarction or unstable angina within the last 3 months.
- • Unwillingness for ablation
- • Unwillingness to be involved in study
- • Suspected reversible cause of AF
- • Any other contraindication to catheter ablation
- • Age \< 18 yrs or \> 80 years
- • Pregnancy
- • Morbid obesity (defined as body mass index \>40)
- • Any other medical problem likely to cause death within the next 18 months
About Barts & The London Nhs Trust
Barts and The London NHS Trust is a leading healthcare organization in the United Kingdom, renowned for its commitment to delivering high-quality clinical care, research, and education. As a prominent sponsor of clinical trials, the Trust is dedicated to advancing medical knowledge and improving patient outcomes through innovative research initiatives. With a focus on patient safety and ethical standards, Barts and The London NHS Trust collaborates with multidisciplinary teams to explore cutting-edge therapies and interventions across various medical fields, ensuring that trial participants receive the highest level of care and support throughout their involvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials